24 results
6-K
EX-99.2
IFRX
InflaRx N.V.
10 Aug 23
Report of Foreign Private Issuer
8:00am
Commercial Officer at Advicenne Pharma SA, a French pharmaceutical company specializing in the development of innovative treatments in Nephrology
6-K
EX-99.1
IFRX
InflaRx N.V.
28 Jun 23
InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer
8:30am
innovative anti-C5a / anti-C5aR programs have the potential to be truly life-changing for patients with acute inflammatory conditions as well as many
6-K
EX-99.1
IFRX
InflaRx N.V.
5 Apr 23
Current report (foreign)
4:01pm
Commercial Officer in Advicenne, a French pharmaceutical company specializing in the development of innovative treatments in Nephrology. She is a non
6-K
EX-99.1
IFRX
InflaRx N.V.
21 Dec 22
Current report (foreign)
7:45am
) Biopharmaceuticals Co., Ltd.:
STS (SZSE: 300204) is an innovative biopharmaceutical company dedicated to research and development, production and sales of drugs
6-K
EX-99.1
v2lgp7c
13 Jun 19
Current report (foreign)
9:00am
20-F/A
cb6trnylb f1jlqi
29 Mar 19
Annual report (foreign) (amended)
4:23pm
6-K
EX-99.1
6d4cl p96
27 Feb 19
InflaRx Receives Approval to Initiate Phase IIa Clinical Trial with Lead CandidateIFX-1 in Pyoderma Gangraenosum
8:39am
6-K
EX-99.1
y9k82hhp5846o
14 Feb 19
Current report (foreign)
8:44am
6-K
EX-99.1
13l o9yb73yhskeopcsx
6 Feb 19
InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa
8:35am
6-K
EX-99.1
3f6jfivz
3 Jan 19
InflaRx Continues U.S. Expansion with Addition of New York City Corporate Office and Addition of Management
8:53am
6-K
EX-99.1
roo2u z0wl2
19 Dec 18
InflaRx Receives European Approval to Initiate Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis
8:36am
6-K
EX-99.3
mm58ck2upri7pa7
21 Nov 18
Current report (foreign)
8:34am
6-K
EX-99.1
v37g2 auwhphjdm2n9l
8 Nov 18
InflaRx Completes Enrollment in Phase IIb Clinical Trial with Lead Candidate IFX-1 in Hidradenitis Suppurativa
8:52am
6-K
EX-99.1
ulu84vwonsgm tt2uopl
30 Oct 18
Current report (foreign)
8:21am
6-K
EX-99.1
57t90z2fu480gscd
21 Sep 18
InflaRx N.V. Announces Appointment of Jens Holstein to Board of Directors
8:38am
6-K
EX-99.3
xyvhb6rn5h c28dn
9 Aug 18
Current report (foreign)
7:35am
6-K
EX-99.1
rsb0dv8s9 j9wh1
28 Jun 18
InflaRx Receives IND Approval from the FDA to Start its Phase II Clinical Trial of IFX-1 in ANCA-Associated Vasculitis
7:34am
6-K
EX-99.1
0f8nl99cqwd79w1f6bq
5 Jun 18
Current report (foreign)
12:00am